34-LB: Vitamin D Supplementation and Risk of Type 2 Diabetes in Patients with Prediabetes: A Meta-analysis of Individual Participant Data from Randomized, Placebo-Controlled Trials

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 34-LB
Author(s):  
ANASTASSIOS G. PITTAS ◽  
TETSUYA KAWAHARA ◽  
ROLF JORDE ◽  
JASON P. NELSON ◽  
EDITH ANGELLOTTI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin D ◽  
Meta Analysis ◽  
Vitamin D Supplementation ◽  
Controlled Trials ◽  
Individual Participant Data ◽  
Individual Participant

scholarly journals Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials

Thorax ◽  
2019 ◽  
Vol 74 (4) ◽  
pp. 337-345 ◽  
Author(s):  
David A Jolliffe ◽  
Lauren Greenberg ◽  
Richard L Hooper ◽  
Carolien Mathyssen ◽  
Rachida Rafiq ◽  
...  
Keyword(s):  
Vitamin D ◽  
Meta Analysis ◽  
Vitamin D Supplementation ◽  
Controlled Trials ◽  
Individual Participant Data ◽  
Hydroxyvitamin D ◽  
Copd Exacerbations ◽  
Individual Participant ◽  
25 Hydroxyvitamin D ◽  
Randomised Controlled

BackgroundRandomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results.Individual participant data meta-analysis could identify factors that explain this variation.MethodsPubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science were searched from inception up to and including 5 October 2017 to identify RCTs of vitamin D supplementation in patients with COPD that reported incidence of acute exacerbations. Individual participant data meta-analysis was performed using fixed effects models adjusting for age, sex, Global Initiative for Chronic Obstructive Lung Disease spirometric grade and trial.ResultsFour eligible RCTs (total 560 participants) were identified; individual participant data were obtained for 469/472 (99.4%) participants in three RCTs. Supplementation did not influence overall rate of moderate/severe COPD exacerbations (adjusted incidence rate ratio (aIRR) 0.94, 95% CI 0.78 to 1.13). Prespecified subgroup analysis revealed that protective effects were seen in participants with baseline 25-hydroxyvitamin D levels <25 nmol/L (aIRR 0.55, 95% CI 0.36 to 0.84) but not in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (aIRR 1.04, 95% CI 0.85 to 1.27; p for interaction=0.015). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted OR 1.16, 95% CI 0.76 to 1.75).ConclusionsVitamin D supplementation safely and substantially reduced the rate of moderate/severe COPD exacerbations in patients with baseline 25-hydroxyvitamin D levels <25 nmol/L but not in those with higher levels.Trial registration numberCRD42014013953.

Weniger akute Atemwegsinfekte durch Vitamin-D-Supplementation?

2018 ◽  
Vol 97 (08) ◽  
pp. 524-525
Author(s):  
Klaus Weckbecker
Keyword(s):  
Systematic Review ◽  
Vitamin D ◽  
Respiratory Tract Infections ◽  
Meta Analysis ◽  
Vitamin D Supplementation ◽  
Individual Participant Data ◽  
Individual Participant ◽  
25 Hydroxy Vitamin D ◽  
25 Oh Vitamin D ◽  
Tract Infections

Martineau AR. et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583 Vitamin D spielt Studien zufolge auch eine Rolle bei der Abwehr pathogener Keime: 25-Hydroxy-Vitamin D (25[OH] Vitamin D) unterstützt z. B. die Synthese antimikrobieller Peptide. Es gibt also eine mögliche Erklärung für die Beobachtung, dass Personen mit niedrigen Vitamin-D-Spiegeln besonders empfindlich gegenüber respiratorischen Infekten sind. Untersuchungen zu einer präventiven Wirkung des Vitamin D verliefen jedoch zum Teil widersprüchlich.

Sign in / Sign up

Export Citation Format

Share Document